Endothelial dysfunction is a central pathogenic mechanism linking Type 2 diabetes and insulin resistance to the development of atherosclerotic macroangiopathy.
Answers are grounded in this paper and cite their sources.
Endothelial dysfunction remains a research target in diabetic macroangiopathy; hypothesis-generating for targeted interventions pending prospective trials.
Type 2 diabetes mellitus (DM) represents a high risk condition for the development of atherosclerotic and thromboembolic macroangiopathy, which make major contributions to diabetic mortality and morbidity. While many cardiovascular risk factors are common to both atherosclerosis and Type 2 DM, the enhanced risk of diabetic macroangiopathy may be attributable to additional pro-atherogenic mediators associated with insulin resistance syndrome. Given the central pathogenic role of endotheliopathy in atherosclerosis, it is likely that this vascular monolayer is the ultimate target of injury in response to such mediators. Furthermore, a pro-oxidative, dysfunctional endothelium may actively contribute to the pro-atherogenic environment through an inappropriate regulation of vascular tone, permeability, coagulation, fibrinolysis, cell adhesion and proliferation. Such dysfunction may mediate hypertension, dyslipidaemia and altered haemostasis, in addition to aggravating in vivo insulin resistance.
No takes yet. Share an insight, caveat, or question.
Laight et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: